Grace Therapeutics, Inc. (ACST)
2.12
+0.02
(+0.95%)
USD |
NASDAQ |
Sep 08, 16:00
Grace Therapeutics Enterprise Value : 20.74M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 20.74M |
| September 04, 2026 | 20.42M |
| September 03, 2026 | 21.07M |
| September 02, 2026 | 21.07M |
| September 01, 2026 | 20.42M |
| August 31, 2026 | 20.91M |
| August 28, 2026 | 20.74M |
| August 27, 2026 | 21.40M |
| August 26, 2026 | 21.23M |
| August 25, 2026 | 22.05M |
| August 24, 2026 | 21.72M |
| August 21, 2026 | 22.05M |
| August 20, 2026 | 21.07M |
| August 19, 2026 | 22.05M |
| August 18, 2026 | 20.91M |
| August 17, 2026 | 21.40M |
| August 14, 2026 | 21.40M |
| August 13, 2026 | 19.93M |
| August 12, 2026 | 20.42M |
| August 11, 2026 | 20.74M |
| August 10, 2026 | 20.58M |
| August 07, 2026 | 20.91M |
| August 06, 2026 | 20.74M |
| August 05, 2026 | 21.07M |
| August 04, 2026 | 21.72M |
| Date | Value |
|---|---|
| August 03, 2026 | 20.09M |
| July 31, 2026 | 20.09M |
| July 30, 2026 | 19.93M |
| July 29, 2026 | 20.09M |
| July 28, 2026 | 22.86M |
| July 27, 2026 | 23.67M |
| July 24, 2026 | 24.16M |
| July 23, 2026 | 24.49M |
| July 22, 2026 | 24.81M |
| July 21, 2026 | 25.79M |
| July 20, 2026 | 25.79M |
| July 17, 2026 | 26.44M |
| July 16, 2026 | 25.46M |
| July 15, 2026 | 25.79M |
| July 14, 2026 | 26.28M |
| July 13, 2026 | 25.79M |
| July 10, 2026 | 26.12M |
| July 09, 2026 | 25.95M |
| July 08, 2026 | 26.77M |
| July 07, 2026 | 27.09M |
| July 06, 2026 | 27.42M |
| July 02, 2026 | 24.81M |
| July 01, 2026 | 22.70M |
| June 30, 2026 | 23.19M |
| June 29, 2026 | 19.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 503.91B |
| Abeona Therapeutics, Inc. | 207.82M |
| America Great Health | 7.243M |
| Acumen Pharmaceuticals, Inc. | 149.96M |
| Aardvark Therapeutics, Inc. | 43.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.79M |
| Total Expenses (Quarterly) | 15.79M |
| EPS Diluted (Quarterly) | -0.9143 |
| Earnings Yield | -55.82% |
| Normalized Earnings Yield | -32.83 |